You-Cai Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
You-Cai Xiao has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Allen Chao
The Wistar Institute, Philadelphia, Pennsylvania
15 shared publications - Christine M. Eischen
Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
15 shared publications - Clare M. Adams
Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
15 shared publications - Fen-Er Chen
Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University
15 shared publications - Jitendra Gour
The Wistar Institute, Philadelphia, Pennsylvania
15 shared publications - Joel Cassel
The Wistar Institute, Philadelphia, USA
15 shared publications
Latest Publications
- 8 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 24096-24120
Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) hydrolyzes cGAMP within the tumor microenvironment (TME), suppressing stimulator of interferon genes (STING)-mediated antitumor immunity. Inspired by the phosphate-based inhibitor STF-1084, we developed a novel class of non-nucleotide ENPP1 inhibitors featuring a boronic acid zinc-binding group (ZBG), which led to the identification of the potent and pH-resilient compound 36. In vitro evaluations confirmed that compound 36 enhances cGAMP-mediated STING activation, driving the upregulation of key immune effectors and chemokines. Furthermore, in a syngeneic CT26 tumor model, monotherapy with compound 36 (20 mg/kg, IP) achieved a tumor growth inhibition (TGI) of 57.4%. Notably, combination therapy with a single dose of oxaliplatin (OX) exhibited a synergistic antitumor effect (TGI = 80.7%) without observable toxicity. Collectively, this study identifies compound 36 as a promising lead ENPP1 inhibitor and further highlights boronic acid as an effective ZBG for the development of ENPP1-targeted cancer immunotherapies.
- 8 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 24096-24120
Development of pH-Resilient Boronic Acid ENPP1 Inhibitors for STING-Mediated Cancer Immunotherapy
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) hydrolyzes cGAMP within the tumor microenvironment (TME), suppressing stimulator of interferon genes (STING)-mediated antitumor immunity. Inspired by the phosphate-based inhibitor STF-1084, we developed a novel class of non-nucleotide ENPP1 inhibitors featuring a boronic acid zinc-binding group (ZBG), which led to the identification of the potent and pH-resilient compound 36. In vitro evaluations confirmed that compound 36 enhances cGAMP-mediated STING activation, driving the upregulation of key immune effectors and chemokines. Furthermore, in a syngeneic CT26 tumor model, monotherapy with compound 36 (20 mg/kg, IP) achieved a tumor growth inhibition (TGI) of 57.4%. Notably, combination therapy with a single dose of oxaliplatin (OX) exhibited a synergistic antitumor effect (TGI = 80.7%) without observable toxicity. Collectively, this study identifies compound 36 as a promising lead ENPP1 inhibitor and further highlights boronic acid as an effective ZBG for the development of ENPP1-targeted cancer immunotherapies.
- 8 May 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (20) , 4248-4252
Total synthesis of γ-tocopherol via asymmetric 1,4-conjugate addition of alkyl Grignard reagents to 2-methyl chromone
Cu I /( S , R )-rev-Josiphos-catalyzed asymmetric 1,4-addition of alkyl Grignard reagents to 2-methyl chromones enabled access to chiral tetrasubstituted chromanones with broad scope, excellent regioselectivity, and up to 97% ee.
- 8 May 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (20) , 4248-4252
Total synthesis of γ-tocopherol via asymmetric 1,4-conjugate addition of alkyl Grignard reagents to 2-methyl chromone
Cu I /( S , R )-rev-Josiphos-catalyzed asymmetric 1,4-addition of alkyl Grignard reagents to 2-methyl chromones enabled access to chiral tetrasubstituted chromanones with broad scope, excellent regioselectivity, and up to 97% ee.
- 9 April 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (16) , 5044-5049
Highly Regio- and Enantioselective Catalytic 1,6-Conjugate Addition of Grignard Reagents to Cyclic Dienones
The catalytic asymmetric conjugate additions of alkyl Grignard reagents to cyclic dienones were achieved using an (R)-Sunphos ligand L6. Chiral 2-styryl chromanone and its analogues were produced in high to excellent yields, excellent regioselectivities, and excellent enantioselectivities (82–99% ee’s) with a broad substrate scope. This study expands the asymmetric 1,6-conjugate addition of Grignard reagents from linear dienones to more challenging cyclic dienones, and gram-scale reactions further demonstrate the practical applicability of this protocol.
- 9 April 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (16) , 5044-5049
Highly Regio- and Enantioselective Catalytic 1,6-Conjugate Addition of Grignard Reagents to Cyclic Dienones
The catalytic asymmetric conjugate additions of alkyl Grignard reagents to cyclic dienones were achieved using an (R)-Sunphos ligand L6. Chiral 2-styryl chromanone and its analogues were produced in high to excellent yields, excellent regioselectivities, and excellent enantioselectivities (82–99% ee’s) with a broad substrate scope. This study expands the asymmetric 1,6-conjugate addition of Grignard reagents from linear dienones to more challenging cyclic dienones, and gram-scale reactions further demonstrate the practical applicability of this protocol.
- 24 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 6111-6137
Harnessing Unique Boron Chemistry to Develop a New Class of Non-hydroxamate HDAC Inhibitors with Validated In Vivo Efficacy
Boron’s dynamic covalent reactivity and flexible coordination offer medicinal promise yet remain underexplored in metalloenzyme pharmacophore design. In this study, a series of novel boronic acid–based HDAC inhibitors were designed and further optimized via amide-to-imidazole cyclization to enhance potency and pharmacokinetics. Among these compounds, Z16 showed potent HDAC inhibition (IC50 37.73 nM) and broad-spectrum antiproliferative activity, with IC50 values of 0.02–0.10 μM in various cell lines. In vitro and in vivo pharmacokinetic evaluation revealed that Z16 possesses a set of characteristics─including species-dependent metabolic stability, extensive tissue distribution, and high absolute bioavailability following intraperitoneal administration (i.p.). Z16 also showed comparable antitumor activity in an HCT116 xenograft model without causing significant loss of body weight or toxicity. These findings establish Z16 as a promising lead for nonhydroxamate HDAC inhibitors and highlight boronic acid’s potential as a metalloenzyme-targeted pharmacophore.
- 24 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 6111-6137
Harnessing Unique Boron Chemistry to Develop a New Class of Non-hydroxamate HDAC Inhibitors with Validated In Vivo Efficacy
Boron’s dynamic covalent reactivity and flexible coordination offer medicinal promise yet remain underexplored in metalloenzyme pharmacophore design. In this study, a series of novel boronic acid–based HDAC inhibitors were designed and further optimized via amide-to-imidazole cyclization to enhance potency and pharmacokinetics. Among these compounds, Z16 showed potent HDAC inhibition (IC50 37.73 nM) and broad-spectrum antiproliferative activity, with IC50 values of 0.02–0.10 μM in various cell lines. In vitro and in vivo pharmacokinetic evaluation revealed that Z16 possesses a set of characteristics─including species-dependent metabolic stability, extensive tissue distribution, and high absolute bioavailability following intraperitoneal administration (i.p.). Z16 also showed comparable antitumor activity in an HCT116 xenograft model without causing significant loss of body weight or toxicity. These findings establish Z16 as a promising lead for nonhydroxamate HDAC inhibitors and highlight boronic acid’s potential as a metalloenzyme-targeted pharmacophore.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7
- 8 May 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 293, 117723
Discovery of 3-methacylic acid substituted benzoxaboroles as dual metallo- and serine-β-lactamase inhibitors
- 8 May 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 293, 117723
Discovery of 3-methacylic acid substituted benzoxaboroles as dual metallo- and serine-β-lactamase inhibitors
- 9 April 2024
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 11 (10) , 2917-2921
Organocatalytic formal [4 + 2] cycloaddition of o-quinone-methyl derivatives and 2-isocyanatomalonate diesters for the construction of chroman derivatives with adjacent quaternary chiral centers
An asymmetric organocatalytic formal [4 + 2] cycloaddition/annulation cascade of ortho-quinone methides with 2-isocyanatomalonate diesters has been reported.
- 9 April 2024
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 11 (10) , 2917-2921
Organocatalytic formal [4 + 2] cycloaddition of o-quinone-methyl derivatives and 2-isocyanatomalonate diesters for the construction of chroman derivatives with adjacent quaternary chiral centers
An asymmetric organocatalytic formal [4 + 2] cycloaddition/annulation cascade of ortho-quinone methides with 2-isocyanatomalonate diesters has been reported.
- 18 November 2023
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 19 (2) , 239-251
The vinyl sulfone motif as a structural unit for novel drug design and discovery
Vinyl sulfones are a special sulfur-containing structural unit that have attracted considerable attention, owing to their important role in serving as key structural motifs of various biologically active compounds as well as serving as versatile building blocks for organic transformations. The synthetic strategy of vinyl sulfone derivatives has been substantially upgraded over the past 30 years, and the wide application of this functional group in drug design and discovery has been promoted. In this review, the authors review the application of vinyl sulfones in drug discovery and select optimized compounds which might have significant impact or potential inspiration for drug design. Vinyl sulfones have been reported to target various macromolecular targets via non-covalent or covalent interactions, including multiple kinases, tubulin, cysteine protease, transcription factor, and so on. Thus, it has been significantly applied as a privileged scaffold in the design of anticancer, anti-infective, anti-inflammatory, and neuroprotective agents. However, much work remains to be done to improve the drug-like properties, such as chemical and metabolic stability, ADME, and toxicity. Besides, the chemical space of vinyl sulfones needs to be expanded, including but not limited to the design of constrained endocyclic and exocyclic vinyl sulfones.
- 18 November 2023
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 19 (2) , 239-251
The vinyl sulfone motif as a structural unit for novel drug design and discovery
Vinyl sulfones are a special sulfur-containing structural unit that have attracted considerable attention, owing to their important role in serving as key structural motifs of various biologically active compounds as well as serving as versatile building blocks for organic transformations. The synthetic strategy of vinyl sulfone derivatives has been substantially upgraded over the past 30 years, and the wide application of this functional group in drug design and discovery has been promoted. In this review, the authors review the application of vinyl sulfones in drug discovery and select optimized compounds which might have significant impact or potential inspiration for drug design. Vinyl sulfones have been reported to target various macromolecular targets via non-covalent or covalent interactions, including multiple kinases, tubulin, cysteine protease, transcription factor, and so on. Thus, it has been significantly applied as a privileged scaffold in the design of anticancer, anti-infective, anti-inflammatory, and neuroprotective agents. However, much work remains to be done to improve the drug-like properties, such as chemical and metabolic stability, ADME, and toxicity. Besides, the chemical space of vinyl sulfones needs to be expanded, including but not limited to the design of constrained endocyclic and exocyclic vinyl sulfones.
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chimera (PROTAC) to target it. Our PROTAC selectively targets MDM2 for proteasome-mediated degradation with high-affinity binding and VHL recruitment. MDM2 loss in p53 mutant/deleted TNBC cells in two-dimensional/three-dimensional culture and TNBC patient explants, including relapsed tumors, causes apoptosis while sparing normal cells. Our MDM2-PROTAC is stable in vivo, and treatment of TNBC xenograft-bearing mice demonstrates tumor on-target efficacy with no toxicity to normal cells, significantly extending survival. Transcriptomic analyses revealed upregulation of p53 family target genes. Investigations showed activation and a required role for TAp73 to mediate MDM2-PROTAC–induced apoptosis. Our data, challenging the current MDM2/p53 paradigm, show MDM2 is required for p53-inactivated TNBC cell survival, and PROTAC-targeted MDM2 degradation is an innovative potential therapeutic strategy for TNBC and superior to existing MDM2 inhibitors.Significance:p53-inactivated TNBC is an aggressive, therapy-resistant, and lethal breast cancer subtype. We designed a new compound targeting an unexpected vulnerability we identified in TNBC. Our MDM2-targeted degrader kills p53-inactivated TNBC cells, highlighting the requirement for MDM2 in TNBC cell survival and as a new therapeutic target for this disease.See related commentary by Peuget and Selivanova, p. 1043.This article is highlighted in the In This Issue feature, p. 1027
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Triple-negative breast cancers (TNBC) frequently inactivate p53, increasing their aggressiveness and therapy resistance. We identified an unexpected protein vulnerability in p53-inactivated TNBC and designed a new PROteolysis TArgeting Chimera (PROTAC) to target it. Our PROTAC selectively targets MDM2 for proteasome-mediated degradation with high-affinity binding and VHL recruitment. MDM2 loss in p53 mutant/deleted TNBC cells in two-dimensional/three-dimensional culture and TNBC patient explants, including relapsed tumors, causes apoptosis while sparing normal cells. Our MDM2-PROTAC is stable in vivo, and treatment of TNBC xenograft-bearing mice demonstrates tumor on-target efficacy with no toxicity to normal cells, significantly extending survival. Transcriptomic analyses revealed upregulation of p53 family target genes. Investigations showed activation and a required role for TAp73 to mediate MDM2-PROTAC–induced apoptosis. Our data, challenging the current MDM2/p53 paradigm, show MDM2 is required for p53-inactivated TNBC cell survival, and PROTAC-targeted MDM2 degradation is an innovative potential therapeutic strategy for TNBC and superior to existing MDM2 inhibitors.Significance:p53-inactivated TNBC is an aggressive, therapy-resistant, and lethal breast cancer subtype. We designed a new compound targeting an unexpected vulnerability we identified in TNBC. Our MDM2-targeted degrader kills p53-inactivated TNBC cells, highlighting the requirement for MDM2 in TNBC cell survival and as a new therapeutic target for this disease.See related commentary by Peuget and Selivanova, p. 1043.This article is highlighted in the In This Issue feature, p. 1027
- Open Access
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7
- 9 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Supplementary Materials and Methods, Tables S1-S3, Figures S1-S7